Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia

Leuk Lymphoma. 2015 Mar;56(3):811-3. doi: 10.3109/10428194.2014.935367. Epub 2014 Jul 17.

Authors

Fayez Estephan¹, Heesun J Rogers, Valeria Visconte, Ali Tabarroki, Jing Ai, Hien K Duong, Matt Kalaycio, Ramon V Tiu

Affiliation

¹ Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH , USA.

PMID: 24956141
DOI: 10.3109/10428194.2014.935367

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Bone Marrow Diseases / chemically induced*
Bone Marrow Examination / methods
Dasatinib / therapeutic use*
Female
Humans
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Middle Aged
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / adverse effects*
Remission, Spontaneous

Substances

Protein Kinase Inhibitors
Pyrimidines
Protein-Tyrosine Kinases
nilotinib
Dasatinib